The remaining outcomes were all rated as low or very low quality evidence. Of these outcomes, , QoL (as measured by both the EQ5D VAS (n=679) and KCCQ scales (n=678)), hospitalisation (due to both HF (n=40) and all-cause (n=760)) all showed a clinically important benefit of IV iron (associated with wide confidence intervals around the effect estimate). The outcome ischaemic stroke (n=459) was also rated as very low quality evidence and suggested a clinical harm of IV iron, this was associated with wide confidence intervals around the effect estimate. The remaining outcomes which included mortality,improvement in NHYA class (data on improvement in NYHA has only been extracted where quality of life data is not reported in a trial), discontinuation due to adverse events, drug related vascular disorders, gastrointestinal disorders, nausea and abdominal pain failed to identify any clear clinical effect of IV iron. For the comparison of oral iron with placebo, very low quality evidence was found for the outcomes mortality (n=238, 2 studies), improvement in NYHA class (n=13, study), adverse events (n=225, 1 study) and serious adverse events (n=225, 1 study). The evidence showed a clinically important increase in mortality and clinically important improvement in NHYA class with oral iron (both associated with wide confidence intervals around the effect estimate). Data on improvement in NYHA has only been extracted where quality of life data is not reported in a trial.The evidence for both adverse events and serious adverse events suggested no clinical effect of oral iron. This was also the case for permanent study drug discontinuation which was rated as low quality. The evidence for change in peak VO2, 6 minute walk test distance and KCCQ clinical summary score were reported by the study as median and IQR. Therefore, imprecision could not be assessed. 